Gastroenterología y Hepatología (English Edition)最新文献

{"title":"Assessment of cystic fibrosis related liver disease in a pediatric cohort","authors":"Saioa Vicente-Santamaría ,&nbsp;María Emilia Torres-Guerrero ,&nbsp;Miguel García-González ,&nbsp;Ana Tabares-González ,&nbsp;Celia Gascón-Galindo ,&nbsp;Concepción Marina López-Cárdenes ,&nbsp;Enrique Blitz-Castro ,&nbsp;Ana Morales-Tirado ,&nbsp;María Inmaculada Mota-Goitia ,&nbsp;José Ramón Gutiérrez-Martínez ,&nbsp;Carlos Tutau-Gómez ,&nbsp;Ruth García-Romero ,&nbsp;Enrique Salcedo-Lobato ,&nbsp;Luis Peña-Quintana ,&nbsp;Ana Reyes-Domínguez ,&nbsp;Encarnación Torcuato-Rubio ,&nbsp;Pilar Ortiz-Pérez ,&nbsp;Ana Estefanía Fernández-Lorenzo ,&nbsp;Ana Moreno-Álvarez ,&nbsp;Alfredo Solar-Boga ,&nbsp;David González-Jiménez","doi":"10.1016/j.gastre.2025.502321","DOIUrl":"10.1016/j.gastre.2025.502321","url":null,"abstract":"<div><h3>Background</h3><div>Cystic fibrosis (CF) is an autosomal recessive, chronic, potentially lethal genetic disease. CF manifestations are due to mutations in the CF transmembrane receptor transporter (CFTR) gene which codes for a protein (CFTR) that acts as an anion transporter, mainly chlorine, at epithelial cells where it is expressed. Cystic fibrosis related liver disease (CFRLD) includes a spectrum of hepatobiliary manifestations whose diagnosis and follow-up remains a challenge.</div></div><div><h3>Methods</h3><div>Cross-sectional, descriptive study from 10 Spanish cystic fibrosis units. Clinical and biochemical data obtained. Patients categorized into 3 groups according to liver involvement based on ESPGHAN 2017 criteria. Liver stiffness assessed by transient elastography (TE) and findings from abdominal ultrasound recorded. Statistics performed using SPSS v25.0.</div></div><div><h3>Results</h3><div>We obtained hepatic TE data from 155 pediatric CF patients. Forty-four classified as CFRLD, 38 (86%) had CFRLD without cirrhosis and 6 (14%) had cirrhosis. Fourteen patients without CFRLD (12%) had ultrasound abnormalities. Mean liver elastography value (kPa) was 4.7 (3.5–5.3) in non-CFRLD and 6.09 (4.4–6.7) in CFRLD (<em>p</em> <!-->=<!--> <!-->0.01; <em>T</em> Student [<em>T</em>]).</div></div><div><h3>Conclusions</h3><div>CFRLD is common in children with CF. Transient elastography is a useful method for diagnosis and follow-up, as higher values of TE are found in patients with CFRLD.</div></div>","PeriodicalId":100569,"journal":{"name":"Gastroenterología y Hepatología (English Edition)","volume":"48 5","pages":"Article 502321"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144069371","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sustained jaundice after endoscopic retrograde cholangiopancreatography","authors":"Idoia Agulleiro Beraza,&nbsp;Eduardo Leo Carnerero,&nbsp;José Manuel Sousa Martín,&nbsp;Rose Marie Vallejo Vigo","doi":"10.1016/j.gastre.2025.502264","DOIUrl":"10.1016/j.gastre.2025.502264","url":null,"abstract":"","PeriodicalId":100569,"journal":{"name":"Gastroenterología y Hepatología (English Edition)","volume":"48 5","pages":"Article 502264"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144069373","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inflammatory bowel disease in the gypsy community in England and Scotland","authors":"Affifa Farrukh,&nbsp;John F. Mayberry","doi":"10.1016/j.gastre.2025.502295","DOIUrl":"10.1016/j.gastre.2025.502295","url":null,"abstract":"<div><h3>Introduction</h3><div>The travelling community in England and Scotland may consist of between 150,000 and 500,000 members. In Scotland ethnicity codings for hospital admissions includes: Gypsies, Roma, Irish travellers and show people. Few Trusts in England break down codings for “Other British” in such detail.</div></div><div><h3>Method</h3><div>One hundred and thirty-two NHS Trusts were approached in England and 14 NHS Boards in Scotland through a Freedom of Information request to provide details of admission to hospital between 2016 and 2022 with ulcerative colitis and had undergone a panproctocolectomy and those with Crohn's disease and had undergone a hemicolectomy.</div></div><div><h3>Results</h3><div>Of the 132 NHS Trusts approached in England only 7 were able to provide data on hospital admissions for inflammatory bowel disease from this community; whereas in Scotland 13 of 14 did so. There were 1012 admissions with ulcerative colitis and based on the number of admissions per patient in Somerset NHS Foundation Trust this would represent 138 patients. In contrast, there were 901 admissions with Crohn's disease and at least 9 patients underwent a hemicolectomy.</div></div><div><h3>Conclusion</h3><div>The inadequacy of data collection related to this community is discussed.</div></div>","PeriodicalId":100569,"journal":{"name":"Gastroenterología y Hepatología (English Edition)","volume":"48 5","pages":"Article 502295"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144069370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A rare case of colonic spirochetosis","authors":"Marc Lleixà Rioboo ,&nbsp;Karmele Sáez de Gordoa ,&nbsp;Oswaldo Ortiz","doi":"10.1016/j.gastre.2025.502316","DOIUrl":"10.1016/j.gastre.2025.502316","url":null,"abstract":"","PeriodicalId":100569,"journal":{"name":"Gastroenterología y Hepatología (English Edition)","volume":"48 5","pages":"Article 502316"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144069374","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gallstone ileus due to cholecystocolonic fistula with transverse colon","authors":"Laia Codina Corrons,&nbsp;Maite Santamaría Gómez,&nbsp;Núria Mestres Petit,&nbsp;Alfredo Escartín Arias","doi":"10.1016/j.gastre.2025.502292","DOIUrl":"10.1016/j.gastre.2025.502292","url":null,"abstract":"","PeriodicalId":100569,"journal":{"name":"Gastroenterología y Hepatología (English Edition)","volume":"48 5","pages":"Article 502292"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144069375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From food to alcohol: Why some patients develop new addictions after bariatric surgery","authors":"Edilmar Alvarado-Tapias ,&nbsp;Ramon Bataller ,&nbsp;David Martí-Aguado","doi":"10.1016/j.gastre.2025.502430","DOIUrl":"10.1016/j.gastre.2025.502430","url":null,"abstract":"","PeriodicalId":100569,"journal":{"name":"Gastroenterología y Hepatología (English Edition)","volume":"48 5","pages":"Article 502430"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144069376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Spanish Working Group in Crohn’s Disease and Ulcerative Colitis (GETECCU) position paper on cardiovascular disease in patients with inflammatory bowel disease","authors":"Ignacio Marín-Jiménez ,&nbsp;Daniel Carpio ,&nbsp;Vicent Hernández ,&nbsp;Fernando Muñoz ,&nbsp;Eduardo Zatarain-Nicolás ,&nbsp;Yamile Zabana ,&nbsp;Míriam Mañosa ,&nbsp;Francisco Rodríguez-Moranta ,&nbsp;Manuel Barreiro-de Acosta ,&nbsp;Ana Gutiérrez Casbas","doi":"10.1016/j.gastre.2025.502314","DOIUrl":"10.1016/j.gastre.2025.502314","url":null,"abstract":"<div><div>Cardiovascular diseases (CVD) are the leading cause of death worldwide. Therefore, it is essential to understand their relationship and prevalence in different diseases that may present specific risk factors for them. The objective of this document is to analyze the specific prevalence of CVD in patients with inflammatory bowel disease (IBD), describing the presence of classical and non-classical cardiovascular risk factors in these patients. Additionally, we will detail the pathophysiology of atherosclerosis in this patient group and the different methods used to assess cardiovascular risk, including the use of risk calculators in clinical practice and different ways to assess subclinical atherosclerosis and endothelial dysfunction. Furthermore, we will describe the potential influence of medication used for managing patients with IBD on cardiovascular risk, as well as the potential influence of commonly used drugs for managing CVD on the course of IBD. The document provides comments and evidence-based recommendations based on available evidence and expert opinion. An interdisciplinary group of gastroenterologists specialized in IBD management, along with a consulting cardiologist for this type of patients, participated in the development of these recommendations by the Spanish Group of Work on Crohn’s Disease and Ulcerative Colitis (GETECCU).</div></div>","PeriodicalId":100569,"journal":{"name":"Gastroenterología y Hepatología (English Edition)","volume":"48 5","pages":"Article 502314"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144069377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimizing outcomes with maintenance IV UST in highly bio-exposed patients with IBD. Efficacy and adjusted regimen in real world","authors":"Alejandro Mínguez ,&nbsp;Elena Coello ,&nbsp;Alejandro Garrido ,&nbsp;Paula Ripoll ,&nbsp;María Gomez ,&nbsp;Mariam Aguas ,&nbsp;Marisa Iborra ,&nbsp;Elena Cerrillo ,&nbsp;Lluis Tortosa ,&nbsp;Virginia Bayarri ,&nbsp;Noemí Bueno ,&nbsp;Maria José Fernández ,&nbsp;Remedios Marqués ,&nbsp;Pilar Nos ,&nbsp;Guillermo Bastida","doi":"10.1016/j.gastre.2025.502253","DOIUrl":"10.1016/j.gastre.2025.502253","url":null,"abstract":"<div><h3>Background and aims</h3><div>Ustekinumab is an effective treatment for inflammatory bowel diseases. However, some patients do not respond to conventional doses. The aim of the study was to evaluate the effectiveness of intravenous maintenance ustekinumab in patients with secondary failure.</div></div><div><h3>Methods</h3><div>Single-center, retrospective study in adult patients with intravenous maintenance ustekinumab. The reduction of biochemical activity markers, ustekinumab trough levels and clinical indices of activity were evaluated. Biological remission was defined as the percentage decrease fecal calprotectin ≥80% and/or final fecal calprotectin ≤250 and C reactive protein &lt;5<!--> <!-->mg/L.</div></div><div><h3>Results</h3><div>Thirty-one patients were included: Crohn's disease 77.4%. All included patients were bio-exposed and 61.3% had carried ≥2 biologics.</div><div>Pre-intravenous maintenance mean Harvey–Bradshaw Index was 6.5<!--> <!-->±<!--> <!-->4.38 vs 5<!--> <!-->±<!--> <!-->3.1 at week 8 (<em>p</em> <!-->=<!--> <!-->0.024) vs 4.1<!--> <!-->±<!--> <!-->3.1 at week 24 (<em>p</em> <!-->=<!--> <!-->0.019). The median ustekinumab trough level pre-intravenous maintenance was 1.40<!--> <!-->μg/ml [IQR 2.3] vs 5.35<!--> <!-->μg/ml [IQR 4.1] at week 8 (<em>p</em> <!-->&lt;<!--> <!-->0.001) vs 4.8<!--> <!-->μg/ml [IQR 3.9] at week 24 (<em>p</em> <!-->&lt;<!--> <!-->0.001). The pre-intravenous maintenance median fecal calprotectin was 809<!--> <!-->μg/g [IQR: 2256] vs 423<!--> <!-->μg/g [IQR: 999] at week 8 (<em>p</em> <!-->=<!--> <!-->0.025) vs 333<!--> <!-->μg/g [508] (<em>p</em> <!-->=<!--> <!-->0.001) at week 24.</div><div>At the end of follow-up 48% went into biological remission. The presence of perianal disease was associated with lower biological remission (70.6% vs 27.3%, <em>p</em> <!-->=<!--> <!-->0.025). Median intravenous ustekinumab maintenance time was 8.55 [IQR 23.9] months. In 83.9% of patients no serious infections or malignancy were documented.</div></div><div><h3>Conclusions</h3><div>The use of maintenance intravenous ustekinumab appears to be an effective and safe strategy that can be evaluated as a salvage treatment especially in highly bio-exposed patients.</div></div>","PeriodicalId":100569,"journal":{"name":"Gastroenterología y Hepatología (English Edition)","volume":"48 5","pages":"Article 502253"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144069369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acute cholestatic hepatitis secondary to idiopathic adult ductopenia","authors":"Julia López De-La-Cruz ,&nbsp;María Concepción Aso Gonzalvo ,&nbsp;María Ortíz de Solórzano Reig ,&nbsp;Antonio Aguilar Muñiz ,&nbsp;Marta Latre Santos ,&nbsp;Enrique Ceamanos Ibarra ,&nbsp;María Escuín Sanmartín ,&nbsp;Guillén Bernal Bandrés ,&nbsp;Sergio García Mateo ,&nbsp;Luis Cortés García","doi":"10.1016/j.gastre.2025.502289","DOIUrl":"10.1016/j.gastre.2025.502289","url":null,"abstract":"","PeriodicalId":100569,"journal":{"name":"Gastroenterología y Hepatología (English Edition)","volume":"48 6","pages":"Article 502289"},"PeriodicalIF":0.0,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144166843","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Etrasimod: Review of the efficacy and therapeutic prospects of a new oral therapy for the treatment of ulcerative colitis","authors":"Javier P. Gisbert,&nbsp;María Chaparro","doi":"10.1016/j.gastre.2025.502363","DOIUrl":"10.1016/j.gastre.2025.502363","url":null,"abstract":"<div><div>Etrasimod is a synthetic, non-biological, orally administered small molecule sphingosine-1-phosphate receptor (S1PR) modulator. Etrasimod was approved by the Food and Drug Administration in 2023 and by the European Medicine Agency in 2024, constituting a new therapeutic option for the treatment of moderately to severely active ulcerative colitis in patients 16 years of age and older in the European Union. Its efficacy and tolerability have been demonstrated in several clinical trials both as induction and maintenance treatment, as well as in long-term extension studies. This article reviews the pharmacodynamic characteristics of etrasimod, its main differences with biological drugs and other small molecules (janus kinases inhibitors), as well as its clinical efficacy including certain subpopulations such as patients with isolated ulcerative proctitis, and the impact on their quality of life.</div></div>","PeriodicalId":100569,"journal":{"name":"Gastroenterología y Hepatología (English Edition)","volume":"48 6","pages":"Article 502363"},"PeriodicalIF":0.0,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144166846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}